Fabiflu 800 Co-Pack Tablet contains Favipiravir, an antiviral medication available in two dosages: 800 mg and 200 mg tablets. Favipiravir is primarily used for the treatment of influenza and has gained attention for its potential efficacy against viral infections such as COVID-19. It works by inhibiting the RNA-dependent RNA polymerase enzyme, which is essential for viral replication, thereby reducing the viral load in the body and aiding recovery. The co-pack formulation allows for a convenient dosing regimen, typically starting with a higher dose (800 mg) followed by maintenance doses (200 mg) as prescribed by a healthcare professional. Fabiflu is indicated for mild to moderate viral infections and should be used under medical supervision to ensure appropriate use and to monitor for side effects. Common adverse effects may include gastrointestinal discomfort, elevated liver enzymes, and mild allergic reactions. It is contraindicated in pregnant women due to potential teratogenic effects and should be used cautiously in patients with liver or kidney impairment. Patients are advised to complete the full course of therapy to prevent viral resistance and to follow their healthcare provider’s instructions carefully. Fabiflu 800 Co-Pack Tablet represents an important option in antiviral therapy, especially during viral outbreaks.